1
|
Casadei L, Calore F, Braggio DA, Zewdu A, Deshmukh AA, Fadda P, Lopez G, Wabitsch M, Song C, Leight JL, Grignol VP, Lev D, Croce CM, Pollock RE. MDM2 Derived from Dedifferentiated Liposarcoma Extracellular Vesicles Induces MMP2 Production from Preadipocytes. Cancer Res 2019; 79:4911-4922. [PMID: 31387924 DOI: 10.1158/0008-5472.can-19-0203] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Revised: 06/14/2019] [Accepted: 08/02/2019] [Indexed: 12/15/2022]
Abstract
Dedifferentiated liposarcoma (DDLPS) is frequently diagnosed late, and patients typically respond poorly to treatments. DDLPS is molecularly characterized by wild-type p53 and amplification of the MDM2 gene, which results in overexpression of MDM2 protein, a key oncogenic process in DDLPS. In this study, we demonstrate that extracellular vesicles derived from patients with DDLPS or from DDLPS cell lines are carriers of MDM2 DNA that can be transferred to preadipocytes, a major and ubiquitous cellular component of the DDLPS tumor microenvironment, leading to impaired p53 activity in preadipocytes and increased proliferation, migration, and production of matrix metalloproteinase 2; treatment with MDM2 inhibitors repressed these effects. Overall, these findings indicate that MDM2 plays a crucial role in DDLPS by enabling cross-talk between tumor cells and the surrounding microenvironment and that targeting vesicular MDM2 could represent a therapeutic option for treating DDLPS. SIGNIFICANCE: Extracellular vesicles derived from dedifferentiated liposarcoma cells induce oncogenic properties in preadipocytes.
Collapse
Affiliation(s)
- Lucia Casadei
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - Federica Calore
- Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
| | - Danielle A Braggio
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - Abeba Zewdu
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - Ameya A Deshmukh
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Biomedical Engineering, College of Engineering, The Ohio State University, Ohio
| | - Paolo Fadda
- Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
| | - Gonzalo Lopez
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - Martin Wabitsch
- Department of Pediatrics and Adolescent Medicine Division of Paediatric Endocrinology and Diabetes Centre for Hormonal Disorders in Children and Adolescents, Ulm University Hospital, Germany
| | - Chi Song
- College of Public Health, Division of Biostatistics, The Ohio State University, Columbus, Ohio
| | - Jennifer L Leight
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Biomedical Engineering, College of Engineering, The Ohio State University, Ohio
| | - Valerie P Grignol
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - Dina Lev
- Department of Surgery "B," Sheba Medical Center and The Tel Aviv University, Tel Aviv, Israel
| | - Carlo M Croce
- Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
| | - Raphael E Pollock
- Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
| |
Collapse
|
2
|
Casadei L, Calore F, Deshmukh A, Zewdu A, Braggio DA, Fadda P, Wabitsch M, Lopez G, Leight J, Lev D, Croce CM, Pollock RE. Abstract 1891: Oncogenic MDM2-containing exosomes promote pre-metastatic niche establishment. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-1891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Extracellular vesicles (EVs) have an important role in the communication between cells for their ability to transfer proteins and other biologically active molecules. EVs have been also described to have unique functions during pre-metastatic niche establishment and maintenance. MDM2 oncoprotein is the best-characterized cellular antagonist of p53 and its amplification is one of the most known mechanisms for tumor development. MDM2 amplification occurs in more than forty different types of malignancies and in 100% of well-differentiated and dedifferentiated liposarcoma (DDLPS). Retroperitoneal DDLPS is especially concerning given its propensity for multifocal local and distant recurrence, accounting for an overall survival rate of 10% at 10 years. Here, we show the presence of MDM2 in tumor EVs and specifically in both DDLPS cell line-derived EVs and patient-serum EVs. We also show the ability of MDM2-cargo to be transferred to recipient preadipocytes. Furthermore, we also demonstrated that this transfer is able to promote a pre-metastatic niche establishment in the DDLPS tumor microenvironment fat bearing areas, inducing: (I) tumor associated phenotype such as enhanced proliferation and migration, in the recipient preadipocytes, by downregulation of MDM2 downstream pathway; (II) pro-inflammatory phenotype through the release of pro-inflammatory cytokines such as IL-8; (III) release of active metalloproteinases such as MMP2 which is crucial for the invasiveness of many disseminating tumors. In conclusion here we report the presence of MDM2, in the patient circulation; importantly showing that MDM2 triggers the release of active MMP-2, we also propose a possible mechanism for pre-metastatic niche establishment and DDLPS multifocal loco-regional recurrence.
Citation Format: Lucia Casadei, Federica Calore, Ameya Deshmukh, Abeba Zewdu, Danielle A. Braggio, Paolo Fadda, Martin Wabitsch, Gonzalo Lopez, Jennifer Leight, Dina Lev, Carlo M. Croce, Raphael E. Pollock. Oncogenic MDM2-containing exosomes promote pre-metastatic niche establishment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1891.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Dina Lev
- 3The Tel Aviv University, Tel Aviv, Israel
| | | | | |
Collapse
|
3
|
Casadei L, Calore F, Creighton CJ, Guescini M, Batte K, Iwenofu OH, Zewdu A, Braggio DA, Bill KL, Fadda P, Lovat F, Lopez G, Gasparini P, Chen JL, Kladney RD, Leone G, Lev D, Croce CM, Pollock RE. Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression. Cancer Res 2017; 77:3846-3856. [PMID: 28588009 DOI: 10.1158/0008-5472.can-16-2984] [Citation(s) in RCA: 132] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 03/23/2017] [Accepted: 05/24/2017] [Indexed: 11/16/2022]
Abstract
Despite the development of combined modality treatments against liposarcoma in recent years, a significant proportion of patients respond only modestly to such approaches, possibly contributing to local or distant recurrence. Early detection of recurrent or metastatic disease could improve patient prognosis by triggering earlier clinical intervention. However, useful biomarkers for such purposes are lacking. Using both patient plasma samples and cell lines, we demonstrate here that miR-25-3p and miR-92a-3p are secreted by liposarcoma cells through extracellular vesicles and may be useful as potential biomarkers of disease. Both miR-25-3p and miR-92a-3p stimulated secretion of proinflammatory cytokine IL6 from tumor-associated macrophages in a TLR7/8-dependent manner, which in turn promoted liposarcoma cell proliferation, invasion, and metastasis via this interaction with the surrounding microenvironment. Our findings provide novel and previously unreported insight into liposarcoma progression, identifying communication between liposarcoma cells and their microenvironment as a process critically involved in liposarcoma progression. This study establishes the possibility that the pattern of circulating miRNAs may identify recurrence prior to radiological detectability while providing insight into disease outcome and as a possible approach to monitor treatment efficacy. Cancer Res; 77(14); 3846-56. ©2017 AACR.
Collapse
Affiliation(s)
- Lucia Casadei
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - Federica Calore
- Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
| | - Chad J Creighton
- Department of Medicine and Dan L. Duncan Comprehensive Cancer Center Division of Biostatistics, Houston, Texas
| | - Michele Guescini
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy
| | - Kara Batte
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - O Hans Iwenofu
- Department of Pathology, The Ohio State University, Columbus, Ohio
| | - Abeba Zewdu
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - Danielle A Braggio
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - Kate Lynn Bill
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - Paolo Fadda
- Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
| | - Francesca Lovat
- Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
| | - Gonzalo Lopez
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - Pierluigi Gasparini
- Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
| | - James L Chen
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| | - Raleigh D Kladney
- Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Molecular Genetics, College of Biological Sciences, The Ohio State University (OSU), Columbus, Ohio.,Comprehensive Cancer Center, Columbus, Ohio
| | - Gustavo Leone
- Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.,Department of Molecular Genetics, College of Biological Sciences, The Ohio State University (OSU), Columbus, Ohio.,Comprehensive Cancer Center, Columbus, Ohio
| | - Dina Lev
- Department of Surgery 'B', Sheba Medical Center and The Tel Aviv University, Tel Aviv, Israel
| | - Carlo M Croce
- Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
| | - Raphael E Pollock
- The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. .,Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio
| |
Collapse
|